Related Experiment Video
Updated: Apr 29, 2026
09:34
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
36.1K
Association between NQO1 C609T polymorphism and prostate cancer risk
Zihan Sun1, Yuling Cui, Jing Pei
1Department of Laboratory Diagnosis, General Hospital of Jinan Military Region, 25 Shifan Road, Tianqiao District, Jinan, 250031, Shandong, China.
Summary
The NQO1 C609T polymorphism shows no significant link to prostate cancer risk overall. However, this genetic variation may increase prostate cancer susceptibility in Asian populations, warranting further investigation.
Area of Science:
- Genetics
- Oncology
- Epidemiology
Background:
- Conflicting results exist regarding the association between the NQO1 C609T polymorphism and prostate cancer risk.
- The NAD(P)H:quinone oxidoreductase 1 (NQO1) enzyme plays a role in carcinogen detoxification.
Purpose of the Study:
- To systematically review and meta-analyze published studies to assess the association between the NQO1 C609T polymorphism and prostate cancer risk.
- To investigate potential ethnic differences in this association.
Main Methods:
- A meta-analysis was conducted on 6 eligible studies comprising 717 cases and 1,794 controls.
- Studies were identified from PubMed and the Cochrane Library.
- Statistical analyses were performed using Review Manager 5.0 and Stata 11.0.
Main Results:
- Overall, no significant association was found between the NQO1 C609T polymorphism and prostate cancer risk across additive, recessive, dominant, and allelic models.
- Stratified analysis by race indicated a significant association in Asians under dominant and allelic models (OR = 1.419, P = 0.021; OR = 1.337, P = 0.040, respectively).
- No significant associations were observed in Caucasians.
Conclusions:
- The NQO1 C609T polymorphism may contribute to increased prostate cancer susceptibility in Asian populations.
- Further large-scale, well-designed case-control studies are required to validate these findings.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
189
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
01:05Single Nucleotide Polymorphisms-SNPs
14.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.6K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenomics: Identification of New Drug Targets
120
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
120
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338